Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


αβ-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation.

Kordelas L, Buttkereit U, Lindemann M, Koldehoff M, Klisanin V, Horn PA, Fleischhauer K, Beelen DW.

Bone Marrow Transplant. 2017 Dec;52(12):1668-1670. doi: 10.1038/bmt.2017.185. Epub 2017 Sep 4. No abstract available.


Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies.

Ahci M, Stempelmann K, Buttkereit U, Crivello P, Trilling M, Heinold A, Steckel NK, Koldehoff M, Horn PA, Beelen DW, Fleischhauer K.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1658-1668. doi: 10.1016/j.bbmt.2017.05.031. Epub 2017 Jun 8.


Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.

Danielzik T, Koldehoff M, Buttkereit U, Beelen DW, Horn PA, Lindemann M.

Leuk Lymphoma. 2018 Feb;59(2):490-492. doi: 10.1080/10428194.2017.1330955. Epub 2017 Jun 2. No abstract available.


Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.

Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, Buttkereit U, Opalka B, Lindemann M, Grosse-Wilde H, Seeber S, Moritz T, Nowrousian MR.

Leuk Lymphoma. 2006 Aug;47(8):1570-82.


Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.


In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.

Schütt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-Wilde H, Seeber S, Nowrousian MR, Opalka B, Moritz T.

Cancer Immunol Immunother. 2005 May;54(5):506-12. Epub 2004 Nov 20.


Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.


Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR.

Eur J Haematol. 2005 Jan;74(1):40-6.


Supplemental Content

Loading ...
Support Center